- Oral presentation
- Open Access
Regadenoson blood flow in type 1 diabetes (RABIT1D Study)
© Groves et al.; licensee BioMed Central Ltd. 2014
- Published: 16 January 2014
- Cardiac Magnetic Resonance
- Coronary Artery Calcification
- Myocardial Blood Flow
- Coronary Artery Calcification Score
Cardiovascular disease is the leading cause of mortality in type 1 diabetics (T1D). T1D patients have increased coronary artery calcification (CAC) compared to non-diabetics. We hypothesize that myocardial blood flow (MBF) reserve can be measured in long-standing T1D patients using regadenoson stress cardiac magnetic resonance (CMR) perfusion imaging and is a marker of extensive atherosclerotic disease associated with CAC.
MBF reserve was successfully measured in regadenoson CMR perfusion imaging studies. Regadenoson stress imaging was safe in the T1D patient groups. In this preliminary study, the impaired vasodilator reserve in T1D patients may indicate more extensive atherosclerotic disease than in moderate-risk controls with similar or higher CAC scores.
The CACTI study was supported by National Institutes of Health National Heart, Lung, and Blood Institute grant HL61753. Funding for RABIT1D was provided by Astellas Pharma US Inc.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.